Tysabri News
Timothy L. Vollmer, MD
Professor

Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center
My Educational Video on MS and MS Trials
Produced by www.MSNewsChannel.com
Jennifer
Landry

News Editor
Josi
Creek

News Editor
Desinie
Smith

Senior News Editor
Patti
McArthur

News Editor
Erin
Tysabri
Editor
We Accept No Advertising
  • Founded 2004 by Stan Swartz

  • This site is run by Facebook Volunteers.

    Visit our Facebook Page at:

    facebook.com/StansAngels


    400,000+ Facebook & MySpace Visitors! MS News Channel Visitors:
    HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
    CLICKING ON THE RED BUTTON BELOW
    You'll get FREE Breaking News Alerts on new MS treatments as they are approved
    PLUS: We will notify you when we produce videos like the one below that we filmed with Dr. Timothy Vollmer to help you understand Tysabri's temporary withdrawal from the market
    Timothy L. Vollmer M.D.
    Department of Neurology
    University of Colorado Health Sciences Center
    Co-Director of the RMMSC at Anschutz Medical Center
    and
    Medical Director-Rocky Mountain MS Center


    Click to view 1280 MS Walk photos!

    "MS Can Not
    Rob You of Joy"
    "I'm an M.D....my Mom has MS and we have a message for everyone."
    - Jennifer Hartmark-Hill MD
    Beverly Dean

    "I've had MS for 2 years...this is the most important advice you'll ever hear."
    "This is how I give myself a painless injection."
    Heather Johnson

    "A helpful tip for newly diagnosed MS patients."
    "Important advice on choosing MS medication "
    Joyce Moore

    Previious Posts

    MS NEWS ARCHIVES: by week

    This page is powered by Blogger. Isn't yours?

    Wednesday, April 7

     

    FDA Issues Warning Letters Over Tysabri, ‘Lipodissolve’ Injections


    (Posted By: Josi Creek)

    The FDA today disclosed several warning letters it had sent to drug makers and weight-loss spas for “false” and-or “misleading” claims for their products. Here’s a rundown:
    • Biogen Idec was cited for a promotional Webcast involving the multiple sclerosis drug Tysabri because it minimized the risk of a serious brain infection, the FDA said. The letter also cited the company for failing to submit the Webcast for FDA review 30 days in advance. Tysabri is sold jointly by Biogen and Elan.
    • Gilead Sciences was cited for a print ad for involving its HIV drug Truvada, which the FDA said overstated the effectiveness of the products and minimized the risks associated with the
      drug.
    • Half a dozen spas offering “lipodissolve” injections to get rid of small fat deposits received letters because the FDA said the therapy hasn’t been cleared by regulators. “The claims made for your lipodissolve products are false and misleading in that they are not supported by substantial evidence or substantial clinical experience,” one letter said.
    To read the original story, please click HERE.